Phase Ib/II Study of INC280 + PDR001 or PDR001 Single Agent in Advanced HCC
Status:
Completed
Trial end date:
2021-06-24
Target enrollment:
Participant gender:
Summary
The purpose of this study of INC280 and PDR001 is to characterize the safety, tolerability,
pharmacokinetics (PK), pharmacodynamics (PD) and antitumor activity of PDR001 administered
i.v. as a single agent or in combination with INC280 administered orally in adult patients
with advanced hepatocellular carcinoma (HCC).